Anzeige
Meldung des Tages: Prof. Dr. Dr. Andreas Pfützner: Geniale Lösung für Diabetiker!

Nicox Aktie News

Aktie
WKN:  A143G8 ISIN:  FR0013018124 US-Symbol:  NICXF Branche:  Biotechnologie Land:  Frankreich
0,2938 €
+0,0058 €
+2,01%
23.12.25
Depot/Watchlist
Marktkapitalisierung *
17,62 Mio. €
Streubesitz
85,41%
KGV
-0,62
Index-Zuordnung
-

Nicox News

16.12.25 - GlobeNewswire
Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026
Press Release Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 All clinical trial and long-term stability data required ...
23.10.25 - GlobeNewswire
Nicox Provides First Half 2025 Financial Results
Press Release Nicox Provides First Half 2025 Financial Results  New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and China Company believes ...
02.10.25 - GlobeNewswire
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
Press Release Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-​planned analysis of ...
04.09.25 - GlobeNewswire
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
Press Release Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Company expects to fully repay existing financial debts in 2026 NCX ...
26.08.25 - GlobeNewswire
Nicox Announces Shareholder Q&A Webpage Available
Press Release Nicox Announces Shareholder Q&A Webpage Available August 26, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris ...
21.08.25 - GlobeNewswire
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients
Press Release Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 ...
08.08.25 - GlobeNewswire
Nicox Extends Existing Flexible Equity Financing
Press Release Nicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory ...
05.08.25 - GlobeNewswire
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
Press Release Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for ...
17.07.25 - GlobeNewswire
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 ...
30.06.25 - GlobeNewswire
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-​August to mid-​September 2025 New Drug Application ...
27.05.25 - GlobeNewswire
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
Press Release Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Exclusive Japanese ...
14.05.25 - GlobeNewswire
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial  Several aqueous humor parameters stimulated by nitric oxide were statistically ...
30.04.25 - GlobeNewswire
Nicox Provides Full Year 2024 Financial Results
Press Release Nicox Provides Full Year 2024 Financial Results Nicox SA revenue of €7.9 million for full year 2024  Exceptional income of €13.7 million following the transfer of ...
19.03.25 - GlobeNewswire
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial  Results expected in May 2025 Last patient in the U.S. in the ...
06.03.25 - GlobeNewswire
Nicox Extends Cash Runway into Q4 2025
Press Release Nicox Extends Cash Runway into Q4 2025 Flexible equity financing line with Vester Finance of up to 10,000,000 shares over 24 months Immediate upfront payment ...
03.03.25 - GlobeNewswire
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
Press Release Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update More patients on NCX 470 achieve an intraocular pressure ...
28.01.25 - GlobeNewswire
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025
Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025 January 28, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA ...
21.01.25 - GlobeNewswire
Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights
Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical ...

Newssuche

Videos

newspaper
16.12.25 +1,32%
Technical Trading: DAX Setup mit Kurzfrist Trade
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

DiagnosTear Technologies
DiagnosTear Technologies Inc
0,352 €
-3,83%
DiagnosTear Technologies Inc Chart
Technologischer Geniestreich für die Massen!
Mehr zur Aktie »